Could information improve patient access to new emerging drugs in rare cancer trials?

• Information is a very critical issue for patient access to new emerging drugs in rare cancer trials.
• Information process must be accurately managed in all phases of the trials.
• Information is crucial for patient awareness, empowerment, involvement and participation.